Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms

Human Reproduction

Volumn 12, Issue 3, 1997, Pages 423-429

  Acien P ^a,c   Mauri, M ^b   Gutierrez, M ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c Departamento de Medicina   (Spain)

Author keywords

Cyproterone acetate; GnRH analogues; Hyperandrogenism; Oral contraceptive pill; Polycystic ovarian disease

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; CYPROTERONE ACETATE; ESTRADIOL; ETHINYLESTRADIOL; GLUCOSE; GONADORELIN AGONIST; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; HYDROXYPROGESTERONE; INSULIN; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AMENORRHEA; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INTRAMUSCULAR DRUG ADMINISTRATION; OBESITY; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PATIENT SELECTION; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030915360     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.3.423     Document Type: Article

References (30)

1. Adams, J., Poison, D.W. and Franks, S. (1986) Prevalence of polyeystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J., 293, 355-359.
2. Andreyko, J.L., Monroe, S.E. and Jaffe, R.B. (1986) Treatment of hirsutism with a gonadotrophin-releasing hormone agonist (Naferelin). J. Clin. Endocrinol. Metab., 63, 854-859.
3. Barbieri, R.L. (1992) Hyperandrogenism: new insights into etiology, diagnosis, and therapy. Curr. Opin. Obstet. Gynecol., 4, 372-379.
4. Belisle, S. and Love, E.J. (1986) Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil. Steril., 46, 1015-1020.
5. Carr, B.R., Breslau, N.A., Givens, C. et al. (1995) Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J. Clin. Endocrinol. Metab., 80, 1169-1178.
6. Chang, R.L., Laufer, L.R., Meldrum, D.R. et al. (1983) Steroid hormone secretion in polycystic ovarian disease after ovarian suppression by a long-acting ganadotrophin-releasing hormone agonist. J. Clin. Endocrinol. Metab., 56, 897-903.
7. Ciotta, L., Cianci, A., Calogero, A.E. et al. (1995) Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism, Fertil. Steril., 64, 299-306.
8. Ciotta, L., Cianci, A., Giuffrida, G. et al. (1996) Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil. Steril., 65, 61-67.
9. Corenblum, B. and Baylis, B.W. (1990) Mecial therapy for the syndrome of familial virilization, insulin resistance, and acanthosis nigricans. Fertil. Steril., 53, 421-425.
10. Cusan, L., Dupont, A., Gómez, J.L. et al. (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril., 61, 281-287.
11. De Ziegler, D., Steingold, K., Cerdars, M. et al. (1989) Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab., 68, 1111-1117.
12. Erkind-Hirsch, K.E., Anania, C., Mack, M. and Malinak, R. (1995) Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil. Steril., 63, 970-978.
13. Falsetti, L. and Galbignani, E. (1990) Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception, 42, 611-619.
14. Falsetti, L. and Pasinetti, E. (1994) Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonist in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil. Steril., 61, 817-822.
15. Ferriman, D. and Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab., 21, 1440-1447.
16. Gaspard et al. (1980) Cited by Belisle and Love (1986).
17. Gökmen, O., Senöz, S., Gülekli, B. et al. (1996) Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol. Endocrinol., 10, 249-255.
18. Goni, M., Markussis, V. and Tolis, G. (1994) Efficacy of chronic therapy with the gonadotrophin-releasing hormone agonist decapeptyl in patients with polycystic ovary syndrome. Hum. Reprod., 9, 1048-1052.
19. Guzick, D.S., Wing, R., Smith, K. et al (1994) Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil. Steril., 61, 598-604.
20. Helfer, E.L., Miller, J.L. and Rose, L. (1988) Side-effects of spironolactone therapy in the hirsute woman. J. Clin. Endocrinol. Metab., 66, 208-211.
21. Marcondes, J.A.A., Minnami, S.L., Luthold, W.W. et al. (1992) Treatment of hirsutism in women with fiutamide. Fertil. Steril., 57, 543-547.
22. Moghetti, P., Castello, R., Negri, C. et al. (1995) Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil. Steril., 64, 511-517.
23. Morcos, R.N., Abdul-Malak, M.E. and Shikora, E. (1994) Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil. Steril., 61, 427-431.
24. Neumann, F. (1994) El antiandrogeno acetato de ciproterona: descubrimiento, química, farmacología básica, uso clínico y empleo en investigación básica (Suppl.). Exp. Clin. Endocrinol., 102, 1-32.
25. New, M.I., Lorenzen, F, Lermer, A.J. et al. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J. Clin. Endocrinol. Metab., 57, 320-326.
26. Poyet and Labrie (1985) Cited by Belisle and Love (1986).
27. Pucci, E., Genazzani, A.D., Monzani, F. et al. (1995) Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol. Endocrinol., 9, 221-228.
28. Steingold, K., De Ziegler, D., Cedras, M. et al. (1987) Clinical and hormonal effects of chronic gonadotrophin-releasing hormone agonist treatment in polycystic ovarian disease. J. Clin. Endocrinol. Metab., 65, 773-778.
29. Takahashi, K., Eda, Y., Abu-Musa, A. et al (1994) Transvaginal ultrasound imaging, histopatholoy and endocrinopathy in patients with polycystic ovarian syndrome. Hum. Reprod., 9, 1231-1236.
30. Wysowski, D.K. and Fourcroy, J.L. (1994) Safety of fiutamide. Fertil. Steril., 62, 1089.